Progressive disseminated histoplasmosis (PDH) is caused by Histoplasma capsulatum, a dimorphic fungus found in soil enriched with bat and bird excreta, predominantly in the Ohio and Mississippi River Valleys. It is fatal if untreated, with mortality reaching 50–70% in fulminant cases. [1-2] The disease occurs almost exclusively in immunocompromised hosts and requires aggressive, prolonged antifungal therapy.
1. History
- Onset and tempo: Typically subacute (1–2 months), but 10–20% present with fulminant septic shock [1]
- Constitutional symptoms: Fever (nearly universal), fatigue, weight loss, night sweats [3-4]
- Pulmonary: Cough and dyspnea in ~50% [3]
- GI symptoms: Nausea, vomiting, diarrhea, abdominal pain — present in 50–70% of cases in some series [3]
- Neurologic: Headache, confusion, seizures, focal deficits (CNS involvement in ≤20%) [3]
- Skin/mucosal: Erythematous nodular/ulcerative lesions, oropharyngeal ulcers — more prominent in Latin American presentations [5]
- Exposure history: Residence in or travel to endemic areas; exposure to bat caves, chicken coops, demolition/excavation sites, bird roosts
- Immunosuppression history: HIV/AIDS status and CD4 count, TNF-α inhibitor use, organ transplant, chronic corticosteroids, other immunosuppressive therapy [6-7]
2. Alarm Features
- Septic shock / multiorgan failure (~10% of patients with low CD4 counts) [3]
- Hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome — high mortality [5][8]
- Addisonian crisis from adrenal gland infiltration/destruction [5]
- Pericardial effusion/pericarditis [3]
- CNS involvement: Seizures, altered mental status, focal neurological deficits [3]
- Pancytopenia with coagulopathy [9]
- Rapidly progressive respiratory failure requiring ventilatory support [10]
3. Medications
Induction (moderate-to-severe disease)
- Liposomal amphotericin B 3 mg/kg IV daily for ≥2 weeks (until clinical improvement) — preferred; demonstrated survival benefit over deoxycholate formulation (response 88% vs. 64%, mortality 2% vs. 13%) [3][6][9]
- Amphotericin B lipid complex 5 mg/kg IV daily is an alternative [3]
Step-down / consolidation
- Itraconazole 200 mg PO TID × 3 days (loading), then 200 mg BID for ≥12 months [3]
- Liquid formulation preferred (better absorption); capsules require food and gastric acid [3]
- Monitor random serum itraconazole + hydroxyitraconazole levels — target 1–2 µg/mL; toxicity increases above 5 µg/mL [3]
Mild-to-moderate disseminated disease
CNS disease
- 5 mg/kg IV daily × 4–6 weeks[3]
Alternatives (for itraconazole-intolerant patients)
- Posaconazole 300 mg PO BID × 1 day, then 300 mg daily [3]
- Voriconazole 400 mg PO BID × 1 day, then 200 mg BID [3]
- Fluconazole 800 mg daily — less effective, associated with resistance emergence [3][6]
Contraindicated / ineffective
- Echinocandins (no activity against H. capsulatum) [3]
- Fluconazole is inferior to itraconazole and not recommended as first-line [6][10]
- Azoles should be avoided in the first trimester of pregnancy [3]
Drug interactions: Itraconazole is a moderate CYP3A4 inhibitor — significant interactions with PIs, NNRTIs, and many other medications; check interactions carefully, especially with ART [3]
4. Diet
- No specific dietary triggers
- Itraconazole liquid should be taken on an empty stomach; capsules should be taken with food [3][9]
- Capsules cannot be used with gastric acid–suppressing medications (PPIs, H2 blockers) [3]
- Adequate hydration is important during amphotericin B therapy to mitigate nephrotoxicity
5. Review of Systems
- Constitutional: Fever, chills, night sweats, weight loss, fatigue
- Pulmonary: Cough, dyspnea, pleuritic chest pain
- GI: Nausea, vomiting, diarrhea, abdominal pain, odynophagia (oropharyngeal ulcers)
- Neurologic: Headache, confusion, seizures, vision changes, focal weakness
- Dermatologic: Rash, skin nodules/ulcers, oral lesions
- Hematologic: Easy bruising, bleeding (pancytopenia/coagulopathy)
- Endocrine: Orthostatic symptoms, hypotension (adrenal insufficiency)
- Cardiac: Chest pain, dyspnea on exertion (pericarditis/effusion)
6. Collateral History and Family History
- Collateral: Confirm immunosuppressive medication list, ART adherence, recent CD4 count, prior opportunistic infections, travel/residence in endemic areas
- Occupational/recreational exposures: Spelunking, farming, demolition, landscaping, poultry farming
- Family history: Not a hereditary condition, but household contacts may share environmental exposures
- Social context: Housing conditions, homelessness, incarceration — risk factors for both HIV and environmental exposure
7. Risk Factors
- HIV/AIDS with CD4 ≤200 cells/mm³ — the dominant risk factor; >95% of HIV-associated histoplasmosis presents as disseminated disease [1][3]
- CD4 <50 cells/µL — particularly high risk [11]
- TNF-α inhibitor therapy (infliximab, adalimumab, etc.) [6]
- Solid organ transplant recipients on immunosuppression [7]
- Chronic corticosteroid use
- Hematologic malignancies
- Extremes of age (infants, elderly)
- Residence in or travel to endemic areas (Ohio/Mississippi River Valleys, Central/South America, parts of Africa and Asia) [12]
- Environmental exposures: Bat caves, bird roosts, chicken coops, construction/demolition sites [4]
8. Differential Diagnosis
Histoplasmosis is called the "great imitator" of the fungal world: [13]
- Tuberculosis — the most common clinical mimic; overlapping symptoms, imaging, and epidemiology; co-infection is common [5]
- Non-tuberculous mycobacterial infection (MAC) — similar presentation in advanced HIV
- Cryptococcosis — overlapping CNS and disseminated presentations
- Talaromycosis (Talaromyces marneffei) — in Southeast Asia; skin lesions, pancytopenia
- Lymphoma — fever, weight loss, hepatosplenomegaly, pancytopenia
- Sarcoidosis — granulomatous disease, mediastinal lymphadenopathy
- Leishmaniasis — hepatosplenomegaly, pancytopenia in endemic areas
- Crohn's disease — GI ulcerations can mimic histoplasma colitis [12]
- Other endemic mycoses: Blastomycosis, coccidioidomycosis, paracoccidioidomycosis
Distinguishing features for histoplasmosis: Oropharyngeal ulcers, AST/ALT ratio >2, markedly elevated LDH and ferritin, and positive urine/serum Histoplasma antigen help differentiate from other OIs [1][5][11]
9. Past Medical History
- HIV/AIDS status and nadir CD4 count — most critical
- Prior opportunistic infections
- History of histoplasmosis (reactivation vs. reinfection)
- Organ transplant history
- Autoimmune disease on immunosuppressive therapy
- Chronic lung disease (COPD — risk for chronic cavitary form)
- Adrenal insufficiency (may be caused by histoplasmosis itself)
10. Physical Exam
- Vitals: Fever (nearly universal), tachycardia, hypotension (septic shock or adrenal crisis)
- General: Cachectic, ill-appearing
- HEENT: Oropharyngeal/palatal ulcers — important diagnostic clue [5]
- Lymph nodes: Generalized lymphadenopathy [1]
- Lungs: Crackles, decreased breath sounds; may be normal
- Abdomen: Hepatomegaly, splenomegaly (key finding) [1][3]
- Skin: Papular, nodular, or ulcerative lesions; may resemble molluscum contagiosum in HIV [4]
- Neuro: Meningismus, altered mental status, focal deficits (if CNS involvement)
- Cardiac: Muffled heart sounds, pericardial friction rub (pericarditis/effusion)
11. Lab Studies
Recommended initial labs
- CBC with differential — expect pancytopenia [1][9]
- CMP — elevated AST > ALT (AST/ALT ratio >2 is suggestive), elevated alkaline phosphatase [1][11]
- LDH — often markedly elevated [1]
- Ferritin — often markedly elevated; if extremely high, consider HLH [1][5]
- Coagulation studies (PT/INR, fibrinogen, D-dimer) — coagulopathy/DIC in severe cases
- Blood cultures (lysis-centrifugation technique) — positive in >85% of HIV-associated PDH, but takes weeks [3]
- Histoplasma urine antigen (EIA) — sensitivity ~96–100% in disseminated disease; the single most useful rapid diagnostic test [3][14]
- Histoplasma serum antigen — sensitivity ~92% [3]
- HIV testing if status unknown; CD4 count
- Cortisol level / ACTH stimulation test if adrenal insufficiency suspected
- Peripheral blood smear — may show intracellular yeast within WBCs [1][3]
Monitoring during treatment
- Histoplasma antigen levels (urine and serum) — progressive decline expected; monitor during therapy and for 1 year after to detect relapse [9]
- Itraconazole serum levels at 2 weeks — target 1–2 µg/mL [3]
- Renal function and electrolytes during amphotericin B therapy
- LFTs during azole therapy
12. Imaging
- Chest X-ray (first-line): Diffuse interstitial reticulonodular ("miliary") pattern is classic in disseminated disease; may also show mediastinal lymphadenopathy or diffuse infiltrates [1]
- CT chest: Better characterizes miliary nodules, lymphadenopathy, cavitary disease
- CT abdomen/pelvis: Hepatosplenomegaly, lymphadenopathy, adrenal enlargement (often bilateral — a distinctive finding) [13]
- MRI brain: If CNS symptoms — may show focal parenchymal lesions, meningeal enhancement
- Imaging may be normal in some cases of disseminated disease; a normal CXR does not exclude PDH
13. Special Tests
- Histoplasma urine antigen (lateral flow assay): Point-of-care test with sensitivity 96%, specificity 96% — ideal for rapid ED diagnosis [3]
- Bone marrow biopsy: High yield for diagnosis; shows intracellular yeast on GMS/PAS staining; also evaluates for HLH [1]
- Tissue biopsy (skin, lymph node, liver, GI): Histopathology with GMS or PAS staining reveals 2–4 µm oval yeast with single budding inside macrophages [6][10]
- BAL with antigen testing: Useful for pulmonary involvement [3]
- CSF analysis (if CNS suspected): Lymphocytic pleocytosis, elevated protein, low glucose; CSF Histoplasma antigen and antibody testing [3]
- Serologies (complement fixation, immunodiffusion): Less useful in immunocompromised patients (sensitivity only 41–69% in HIV) [9]
- Diagnostic predictive score (Hoyos Pulgarín et al.): Hemoglobin <10, leukopenia, elevated LDH, AST/ALT ratio >2, CD4 <50 — cutoff ≥4 points yields 82.9% specificity [11]
14. ECG
- Obtain ECG if pericardial involvement suspected
- Look for: Low voltage, electrical alternans (large effusion), diffuse ST elevation (pericarditis), sinus tachycardia
- Baseline ECG recommended before starting azole therapy (QTc prolongation risk with itraconazole, voriconazole, posaconazole)
15. Assessment
Severity stratification
- Mild-to-moderate: Fever, constitutional symptoms, no hemodynamic instability, no organ failure → outpatient itraconazole may be appropriate
- Moderate-to-severe: Significant systemic illness, cytopenias, organ involvement → requires IV amphotericin B induction
- Fulminant/critical: Septic shock, multiorgan failure, HLH, respiratory failure → ICU admission, aggressive resuscitation, immediate amphotericin B [1][3]
Typical presentation: Subacute febrile illness with weight loss, hepatosplenomegaly, and pancytopenia in an immunocompromised host from an endemic area.
Atypical presentations: Isolated GI disease mimicking IBD, adrenal crisis, isolated skin lesions, or fever of unknown origin. Median time to diagnosis is prolonged (~32 days), highlighting the need for high clinical suspicion. [7]
Complications: HLH, adrenal insufficiency, DIC, IRIS (in HIV patients starting ART), pericardial tamponade [3][5][8]
16. Treatment Plan
Initial stabilization (ED)
- ABCs, IV access, fluid resuscitation if hypotensive
- Vasopressors if septic shock
- Stress-dose steroids if adrenal crisis suspected (hydrocortisone 100 mg IV)
Antifungal therapy — initiate promptly
Additional management
- If on TNF-α inhibitors: discontinue during antifungal therapy; may reinstitute after ~12 months of treatment and negative antigen testing [6]
- If HIV-positive: Initiate or optimize ART; monitor for IRIS (continue ART + antifungals if IRIS occurs) [9]
- Secondary prophylaxis with itraconazole may be needed in severely immunosuppressed patients (CD4 <150) who relapse [9]
17. Disposition
- Admit (most patients): ~96% of PDH patients require hospitalization [7]
- All moderate-to-severe disease requiring IV amphotericin B
- Hemodynamic instability, respiratory failure, altered mental status
- Significant cytopenias, coagulopathy
- Suspected HLH, adrenal crisis, or CNS involvement
- ICU admission: Septic shock, multiorgan failure, respiratory failure, pericardial tamponade
- Outpatient management (rare): Only for truly mild disseminated disease in a reliable patient who can take oral itraconazole with close follow-up
- Infectious disease consultation: Recommended for all cases of disseminated histoplasmosis
18. Follow Up / Return Precautions
Follow-up timing
- Itraconazole serum level at 2 weeks after initiation [3]
- Histoplasma antigen levels (urine/serum) during therapy and for 12 months after completion to detect relapse [9]
- Antigenuria recurs in ~90% of patients who relapse [9]
- CD4 monitoring in HIV patients — secondary prophylaxis may be discontinued when CD4 >150 cells/mm³ sustained on ART
Return precautions — seek immediate care for
- Recurrent fevers, worsening fatigue, or new weight loss (relapse)
- New headache, confusion, seizures (CNS disease)
- Orthostatic dizziness, syncope (adrenal insufficiency)
- New skin lesions or oral ulcers
- GI bleeding, severe diarrhea
Patient counseling
- Treatment duration is prolonged (≥12 months) — adherence is critical
- Itraconazole must be taken consistently with attention to formulation-specific instructions
- Avoid re-exposure to high-risk environments (bat caves, bird roosts, demolition sites)
- Expected clinical improvement within 1–2 weeks of amphotericin B initiation [10]
References
1. Fungal Infections in HIV/AIDS. — Limper AH, Adenis A, Le T, Harrison TS. The Lancet. Infectious Diseases. 2017.
2. Treating Progressive Disseminated Histoplasmosis in People Living With HIV. — Murray M, Hine P. The Cochrane Database of Systematic Reviews. 2020.
3. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
4. Progressive Disseminated Histoplasmosis in HIV-positive Patients. — Adamian CMC, de Lima Mota MA, Martins AAF, et al. International Journal of STD & AIDS. 2022.
5. Histoplasmosis: A Missing Piece in the Global Efforts to End HIV Deaths. — Pasqualotto AC, Le T, Vieceli T, et al. The Lancet. HIV. 2026.
6. Global Guideline for the Diagnosis and Management of the Endemic Mycoses: An Initiative of the European Confederation of Medical Mycology in Cooperation With the International Society for Human and Animal Mycology. — Thompson GR, Le T, Chindamporn A, et al. The Lancet. Infectious Diseases. 2021.
7. Progressive Disseminated Histoplasmosis: The Experience in One Non-Endemic Medical Center. — Li LX, Rajack STA, Ostrander D, et al. Medical Mycology. 2023.
8. Progressive Disseminated Histoplasmosis With Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis. — Hall AD, Salibindla D, Dubocq-Cabrera L, et al. The American Journal of Tropical Medicine and Hygiene. 2025.
9. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
10. Coccidioidomycosis and Histoplasmosis in Immunocompetent Persons. — Galgiani JN, Kauffman CA. The New England Journal of Medicine. 2024.
11. Development of a Diagnostic Score for Histoplasmosis in a Cohort of Patients With HIV. — Hoyos Pulgarín JA, Moreno Gómez GA, Atehortua Otero MÁ, Cortés I, Jaramillo Heredia A. Open Forum Infectious Diseases. 2025.
12. Current Concepts in the Epidemiology, Diagnosis, and Management of Histoplasmosis Syndromes. — Azar MM, Loyd JL, Relich RF, Wheat LJ, Hage CA. Seminars in Respiratory and Critical Care Medicine. 2020.
13. Neglected Endemic Mycoses. — Queiroz-Telles F, Fahal AH, Falci DR, et al. The Lancet. Infectious Diseases. 2017.
14. Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary and Critical Care Practice. An Official American Thoracic Society Clinical Practice Guideline. — Hage CA, Carmona EM, Epelbaum O, et al. American Journal of Respiratory and Critical Care Medicine. 2019.